NAGIOS: RODERIC FUNCIONANDO

SARS-CoV-2 Immunity in Hematopoietic Stem Cell Transplant and Cell Therapy Recipients : What Do We Know, and What Remains to Be Determined?

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

SARS-CoV-2 Immunity in Hematopoietic Stem Cell Transplant and Cell Therapy Recipients : What Do We Know, and What Remains to Be Determined?

Mostra el registre parcial de l'element

dc.contributor.author Piñana, José Luis
dc.contributor.author Guerreiro, Manuel
dc.contributor.author Solano Vercet, Carlos
dc.date.accessioned 2023-06-20T14:05:21Z
dc.date.available 2023-06-20T14:05:21Z
dc.date.issued 2023
dc.identifier.citation Piñana, José Luis Guerreiro, Manuel Solano Vercet, Carlos 2023 SARS-CoV-2 Immunity in Hematopoietic Stem Cell Transplant and Cell Therapy Recipients : What Do We Know, and What Remains to Be Determined? Hemato 4 2 170 183
dc.identifier.uri https://hdl.handle.net/10550/88367
dc.description.abstract Hematopoietic stem cell transplantation (HSCT) results in profound immunosuppression for the first few months after the procedure, requiring patients to be revaccinated against childhood vaccine-preventable infectious diseases. Patients who undergo allo-HSCT are at high risk of bacterial, fungal, and viral infections, with infectious complications responsible for at least one third of deaths. Even before the COVID-19 pandemic, respiratory virus infections were known to be more severe in HSCT recipients. The pandemic has highlighted the vulnerability of HSCT recipients, who experience an increased risk of morbidity and mortality after COVID-19 compared with healthy populations due to their severe immunodeficiency status. However, the current pandemic has also provided an exceptional scenario to better understand the immune response to SARS-CoV-2 cases and mRNA vaccines in HSCT recipients, including those receiving CD19-directed chimeric antigen receptor T cell (CAR-T) therapy. Researchers have focused on the role of the immune system in protecting against severe SARS-CoV-2 in patients with hematologic malignancies, including HSCT recipients. Insights gained during the pandemic will likely soon be used to improve preventive strategies in this population against viral infections in the near future. This narrative review summarizes the current knowledge on SARS-CoV-2 immunity in HSCT and cell therapy recipients following SARS-CoV-2 cases or vaccination.
dc.relation.ispartof Hemato, 2023, vol. 4, num. 2, p. 170-183
dc.subject Virus
dc.subject Virus RNA
dc.subject Malalties transmissibles Prevenció
dc.title SARS-CoV-2 Immunity in Hematopoietic Stem Cell Transplant and Cell Therapy Recipients : What Do We Know, and What Remains to Be Determined?
dc.type journal article
dc.date.updated 2023-06-20T14:05:21Z
dc.identifier.doi 10.3390/hemato4020014
dc.identifier.idgrec 160527
dc.rights.accessRights open access

Visualització       (1.028Mb)

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre parcial de l'element

Cerca a RODERIC

Cerca avançada

Visualitza

Estadístiques